Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants

Pediatric Infectious Disease Journal

Volumn 17, Issue 4, 1998, Pages 294-304

  Lagos, Rosanna ^a,b   Kotloff, Karen ^c   Hoffenbach, Agnès ^d   San Martin, Oriana ^a,b   Abrego, Paulina ^a,b   Ureta, Ana Maria ^a,b   Pines, Emmanuelle ^d   Blondeau, Christine ^d   Bailleux, Fabrice ^d   Levine, Myron M ^a,c  

^a Centro para Vacunas en Desarrollo Chile   (Chile)

^b Servicio de Salud Metropolitano Norte   (Chile)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d Pasteur Mérieux Connaught ^*  (France)

Author keywords

Acellular pertussis vaccine; Combination vaccine; Diphtheria vaccine; Haemophilus infiuenzae type b conjugate vaccine; Inactivated poliovirus vaccine; Safety and immunogenicity; Tetanus vaccine

Indexed keywords

BACTERIAL ANTIGEN; DIPLOID CELL VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MEASLES MUMPS RUBELLA VACCINE; TRIVALENT ORIMUNE; UNCLASSIFIED DRUG;

ARTICLE; DIPHTHERIA; DROWSINESS; DRUG SAFETY; ERYTHEMA; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; INFANT; IRRITABILITY; PERTUSSIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; RASH; TETANUS; VACCINATION;

ADHESINS, BACTERIAL; ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; CHILE; DIPHTHERIA TOXIN; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS VACCINES; HEMAGGLUTININS; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INFANT; MALE; POLIOVIRUS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL; TETANUS TOXIN; TETANUS TOXOID; TOXOIDS; VACCINES, COMBINED; VACCINES, CONJUGATE; VIRULENCE FACTORS, BORDETELLA;

EID: 0031970129     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199804000-00006     Document Type: Article

References (28)

1. Lee JW, Aylward B, Hull HF, Batson A, Birmingham E, Lloyd J. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds. New generation vaccines. 2nd ed., revised and expanded. New York: Dekker, 1997:79-88.
2. Centers for Disease Control. Certification of poliomyelitis eradication: the Americas. MMWR 1994;43:720-2.
3. Strebel PM, Sutter RW, Cochi, SL, et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 1992;14:568-79.
4. American Academy of Pediatrics Committee on Infectious Diseases. Poliomyelitis prevention: recommendations for use of inactivated poliovirus vaccine and live oral poliovirus vaccine. Pediatrics 1997;99:300-5.
5. Cherry JD, Brunell PA, Golden GS, Karzon DT. Report of the task force on pertussis and pertussis immunization. Pediatrics 1988;81(Suppl):933-84.
6. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996;334:349-55.
7. Greco DGD, Salmaso S, Biol D, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 1996;334:341-8.
8. Schmitt HJ, von Konig CH, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996;275:37-41.
9. Centers for Disease Control. FDA approval of a second acellular pertussis vaccine for use among infants and young children. MMWR 1997;46:110-1.
10. American Academy of Pediatrics Committee on Infectious Diseases. Acellular pertussis vaccine: recommendations for use as the initial series in infants and children. Pediatrics 1997;99: 282-8.
11. Adams WG, Deaver KA, Cochi SL, et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA. 1993;269:221-6.
12. Peltola H, Kilpi T, Anttila M. Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunisation with conjugate vaccines. Lancet 1992; 340:592-4.
13. Baker JD, Halperin SA, Edwards K, Miller B, Decker M, Stephens D. Antibody response to Bordetella pertussis antigens after immunization with American and Canadian whole-cell vaccines. J Pediatr 1992;121:523-7.
14. Robertson HE, Acker MS, Dillenberg HO. Community-wide use of a "balanced" trivalent oral poliovirus vaccine (Sabin). Can J Public Health 1962;53:179-91.
15. Ferreccio C, Clemens JD, Avendano A, et al. The clinical and immunologic response of Chilean infants to Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine co-administered in the same syringe with DTP at two, four and six months of age. Pediatr Infect Dis J 1991;10:764-71.
16. Auerbach BS, Wilson ME, Lake AM, Deforest A, Steinhoff M, Halsey NA. Dose-response to acellular pertussis vaccine and comparison with whole cell pertussis vaccine at 15-24 months and 4-6 years of age. Acellular Pertussis Vaccine Study Team. Vaccine 1992;10:14-20.
17. Simondon F, Yam A, Gagnepain JY, Wassilak S, Danve B, Cadoz M. Comparative safety and immunogenicity of an acellular versus whole-cell pertussis component of diphtheria-tetanus-pertussis vaccines in Senegalese infants. Eur J Clin Microbiol Infect Dis 1996;15:927-32.
18. David T, Groupe de Pediatres de la Region Lyonnaise, Cadoz M, Gobert P, Danve, B. Acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated polio vaccine (AcPDT IPV): comparison to a DTP-IPV with a whole cell pertussis component (WcPDT IPV) in infants [Abstract 60]. Presented at the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1991:108.
19. Simondon F, Preziosi MP, Yam A, et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 1997;15: 1606-12.
20. Svenson SB, Larson K. An enzyme-linked immunosorbent assay (ELISA) for the determination of diphtheria toxin antibodies. J Immunol Methods 1977;17:249-56.
21. Simonsen O, Bentson MW, Heron I. ELISA for the routine determination of immunity to tetanus. J Biol Stand 1986;14: 231-9.
22. Manclark CR, Meade BD, Burstyn DG. In: Rose NR, Friedman H, Fahey JL, eds. Manual of clinical laboratory immunology. Washington, DC: American Society for Microbiology, 1986:388-94.
23. Kuo JS, Monji N, Schwalbe RS, McCoy DW. A radioactive antigen-binding assay for the measurement of antibody to Haemophilus influenzae type b capsular polysaccharide. J Immunol Methods 1981;43:35-47.
24. Onorato I, Modlin JF, McBean AM, Thomas ML, Losonsky GA, Bernier RH. Mucosal immunity induced by enhanced potency IPV and OPV. J Infect Dis 1991;160:25-31.
25. Clemens JD, Ferreccio C, Levine MM, et al. Impact of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine on responses to concurrently administered diphtheria-tetanus-pertussis vaccine. JAMA 1992;267:673-8.
26. Avendaño A, Ferreccio C, Lagos R, et al. Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine does not depress serologic responses to diphtheria, tetanus or pertussis antigens when coadministered in the same syringe with diphtheria-tetanus-pertussis vaccine at two, four and six months of age. Pediatr Infect Dis J 1993;12:638-43.
27. Levine OS, Granoff D, Lagos R, Fritzell B, Levine MM. Factors associated with a superior antibody response to a single dose of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine administered to Chilean infants at 2 months of age. Vaccine 1997;15:325-8.
28. WHO meeting on case definition of pertussis, Geneva, January 10 to 11, 1991. Issue no. MIM/EPI/PERT/91.1. Geneva: WHO, 1991:4-5.